Chromosome 3 status combined with BAP1 and EIF1AX mutation profiles are associated with metastasis in uveal melanoma

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 8, 2014, Pages 5160-5167

  Ewens, Kathryn G ^a   Kanetsky, Peter A ^b   Richards Yutz, Jennifer ^a   Purrazzella, Juliana ^a   Shields, Carol L ^c   Ganguly, Tapan ^a   Ganguly, Arupa ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

BAP1; Chromosome 3; EIF1AX; GNA11; GNAQ; SF3B1; Somatic mutation; Uveal melanoma

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; CHROMOSOME 3; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC PROCEDURES; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; MONOSOMY; MONOSOMY 3; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; SANGER SEQUENCING; TUMOR VOLUME; UVEA MELANOMA;

BAP1; CHROMOSOME 3; EIF1AX; GNA11; GNAQ; SF3B1; SOMATIC MUTATION; UVEAL MELANOMA;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHROMOSOMES, HUMAN, PAIR 3; DNA MUTATIONAL ANALYSIS; EUKARYOTIC INITIATION FACTOR-1; FEMALE; GTP-BINDING PROTEIN ALPHA SUBUNITS; HUMANS; LOGISTIC MODELS; MALE; MELANOMA; MIDDLE AGED; MUTATION; PHOSPHOPROTEINS; RIBONUCLEOPROTEIN, U2 SMALL NUCLEAR; TIME FACTORS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE; UVEAL NEOPLASMS; YOUNG ADULT;

EID: 84907621350     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-14550     Document Type: Article

References (52)

1. Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003; 44: 4651-4659.
2. Lorigan JG, Wallace S, Mavligit GM. The prevalence and location of metastases from ocular melanoma: imaging study in 110 patients. AJR Am J Roentgenol. 1991; 157: 1279-1281.
3. Paul EV, Parnell BL, Fraker M. Prognosis of malignant melanomas of the choroid and ciliary body. Int Ophthalmol Clin. 1962; 2: 387-402.
4. Aalto Y, Eriksson L, Seregard S, Larsson O, Knuutila S. Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. Invest Ophthalmol Vis Sci. 2001; 42: 313-317.
5. Damato B, Coupland SE. A reappraisal of the significance of largest basal diameter of posterior uveal melanoma. Eye. 2009; 23: 2152-2162.
6. Damato B, Dopierala J, Klaasen A, van Dijk M, Sibbring J, Coupland SE. Multiplex ligation-dependent probe amplification of uveal melanoma: correlation with metastatic death. Invest Ophthalmol Vis Sci. 2009; 50: 3048-3055.
7. Damato B, Dopierala JA, Coupland SE. Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. Clin Cancer Res. 2010; 16: 6083-6092.
8. Damato B, Duke C, Coupland SE, et al. Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology. 2007; 114: 1925-1931.
9. Damato B, Eleuteri A, Taktak AFG, Coupland SE. Estimating prognosis for survival after treatment of choroidal melanoma. Prog Retin Eye Res. 2011; 30: 285-295.
10. Kilic E, Naus NC, van Gils W, et al. Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased disease-free survival in uveal melanoma patients. Invest Ophthalmol Vis Sci. 2005; 46: 2253-2257.
11. Prescher G, Bornfeld N, Hirche H, et al. Prognostic implications of monosomy 3 in uveal melanoma. Lancet. 1996; 347: 1222-1225.
12. Shields CL, Furuta M, Thangappan A, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009; 127: 989-998.
13. Sisley K, Rennie IG, Parsons MA, et al. Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer. 1997; 19: 22-28.
14. White VA, Chambers JD, Courtright PD, Chang WY, Horsman DE. Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma. Cancer. 1998; 83: 354-359.
15. Ewens KG, Kanetsky PA, Richards-Yutz J, et al. Genomic profile of 320 uveal melanoma cases: chromosome 8p-loss and metastatic outcome. Invest Ophthalmol Vis Sci. 2013; 54: 5721-5729.
16. Malignant melanoma of the uvea. In: Edge SB, Byrd DR, Compton CC, et al, eds. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010: 547-559.
17. Kujala E, Damato B, Coupland SE, et al. Staging of ciliary body and choroidal melanomas based on anatomic extent. J Clin Oncol. 2013; 31: 2825-2831.
18. Onken MD, Worley LA, Char DH, et al. Collaborative ocular oncology group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology. 2012; 119: 1596-1603.
19. Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004; 64: 7205-7209.
20. Onken MD, Worley LA, Tuscan MD, Harbour JW. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn. 2010; 12: 461-468.
21. van Gils W, Lodder EM, Mensink HW, et al. Gene expression profiling in uveal melanoma: two regions on 3p related to prognosis. Invest Ophthalmol Vis Sci. 2008; 49: 4254-4262.
22. Worley LA, Onken MD, Person E, et al. Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. Clin Cancer Res. 2007; 13: 1466-1471.
23. Harbour JW, Onken MD, Roberson EDO, et al. Frequent mutation ofBAP1in metastasizing uveal melanomas. Science. 2010; 330: 1410-1413.
24. Onken MD, Worley LA, Long MD, et al. Oncogenic mutations in GNAQoccur early in uveal melanoma. Invest Ophthalmol Vis Sci. 2008; 49: 5230-5234.
25. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations ofGNAQin uveal melanoma and blue naevi. Nature. 2009; 457: 599-602.
26. Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations inGNA11in uveal melanoma. N Engl J Med. 2010; 363: 2191-2199.
27. Harbour JW, Roberson EDO, Anbunathan H, Onken MD, Worley LA, Bowcock AM. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet. 2013; 45: 133-135.
28. Martin M, Maszhofer L, Temming P, et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet. 2013; 45: 933-936.
29. Furney SJ, Pedersen M, Gentien D, et al. SF3B1mutations are associated with alternative splicing in uveal melanoma. Cancer Discov. 2013; 3: 1122-1129.
30. Pópulo H, Vinagre J, Lopes JM, Soares P. Analysis ofGNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas. Br J Ophthalmol. 2011; 95: 715-719.
31. Daniels AB, Lee J-E, MacConaill LE, et al. High throughput mass spectrometry-based mutation profiling of primary uveal melanoma. Invest Ophthalmol Vis Sci. 2012; 53: 6991-6996.
32. Kong Y, Krauthammer M, Halaban R. Rare SF3B1 R625 mutations in cutaneous melanoma. Melanoma Res. 2014; 24: 332-334.
33. Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012; 486: 353-360.
34. Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011; 365: 1384-1395.
35. Wang L, Lawrence MS, Wan Y, et al. SF3B1and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011; 365: 2497-2506.
36. Abdel-Rahman MH, Pilarski R, Cebulla CM, et al. Germline BAP1mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet. 2011; 48: 856-859.
37. Bott M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1is commonly inactivated by somatic mutations and 3p21. 1 losses in malignant pleural mesothelioma. Nat Genet. 2011; 43: 668-672.
38. Carbone M, Ferris L, Baumann F, et al. BAP1cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med. 2012; 10: 179-185.
39. Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G. BAP1and cancer. Nat Rev Cancer. 2013; 13: 153-159.
40. Jensen DE, Rauscher FJ. BAP1, a candidate tumor suppressor protein that interacts with BRCA1. Ann N Y Acad Sci. 1999; 886: 191-194.
41. Murali R, Wiesner T, Scolyer RA. Tumours associated with BAP1mutations. Pathology. 2013; 45: 116-126.
42. Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A, et al. BAP1loss defines a new class of renal cell carcinoma. Nat Genet. 2012; 44: 751-759.
43. Tang J, Xi S, Wang G, et al. Prognostic significance of BRCA1-associated protein 1 in colorectal cancer. Med Oncol. 2013; 30: 1-8.
44. Testa JR, Cheung M, Pei J, et al. GermlineBAP1mutations predispose to malignant mesothelioma. Nat Genet. 2011; 43: 1022-1025.
45. Wiesner T, Obenauf AC, Murali R, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet. 2011; 43: 1018-1021.
46. Cheung M, Talarchek J, Schindeler K, et al. Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma. Cancer Genet. 2013; 206: 206-210.
47. Shields CL, Ganguly A, Materin MA, et al. Chromosome 3 analysis of uveal melanoma using fine-needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases: the Deborah Iverson, MD, Lectureship. Arch Ophthalmol. 2007; 125: 1017-1024.
48. Chen Z, Moran K, Richards-Yutz J, et al. Enhanced sensitivity for detection of low-level germline mosaic RB1 mutations in sporadic retinoblastoma cases using deep semiconductor sequencing. Hum Mutat. 2014; 35: 384-391.
49. Seattle SeqAnnotation 137. Available at: http: //snp. gs. washington. edu/SeattleSeqAnnotation137/. Accessed February 2013.
50. Maat W, Jordanova ES, van Zelderen-Bhola SL, et al. The heterogeneous distribution of monosomy 3 in uveal melanomas: implications for prognostication based on fine-needle aspiration biopsies. Arch Path Lab Med. 2007; 131: 91-96.
51. Onken MD, Worley LA, Davila RM, Char DH, Harbour JW. Prognostic testing in uveal melanoma by transcriptomic profiling of fine needle biopsy specimens. J Mol Diagn. 2006; 8: 567-573.
52. Griewank KG, van de Nes J, Schilling B, et al. Genetic and clinico-pathologic analysis of metastatic uveal melanoma. Mod Pathol. 2014; 27: 175-183.